# JPMorgan Chase & Co.

Type: Company (JPM)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/jpmorgan-chase-co-company
Canonical HTML page: https://getbiobrief.com/entity/jpmorgan-chase-co-company

## Timeline

- **2026-03-06**: JPMorgan Disclosure — JPMorgan Chase & Co. reveals its $12.55 million position in the company.
- **2026-02-25**: Insider Activity — CEO Serge Saxonov sells 9,632 shares under a standard trading plan.
- **2026-02-22**: Syon Capital Entry — Syon Capital LLC discloses a new stake in TXG, adding to institutional support.
- **2026-02-20**: Market Momentum — 10x Genomics shares trade up 6.4% as market sentiment begins to shift.

## Recent coverage (4 stories)

### Agenus Upgraded to Buy After 189% Surge Off 12M Low: Analysts Eye $30 Target
2026-08-08 12:53:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Full story: https://getbiobrief.com/story/agenus-upgraded-buy-189-percent-surge

### Teva's $1.91-$2.11 EPS Outlook Misses as Biotech Investors Weigh Risk-Reward
2026-08-05 14:16:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Full story: https://getbiobrief.com/story/teva-fy2026-guidance-biotech

### ResMed’s $270.64 Consensus Hides a 30% Spread in Analyst Targets
2026-07-10 14:14:59 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Full story: https://getbiobrief.com/story/resmed-analyst-divide-biotech-investment

### JPMorgan Discloses $12.55M Stake in 10x Genomics Amid Sector Volatility
2026-03-06 11:03:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

JPMorgan Chase & Co. has established a significant $12.55 million position in 10x Genomics, signaling institutional confidence in the spatial biology leader. This move comes as the biotech tools sector navigates a complex landscape of patent litigation and shifting R&D budgets.
Full story: https://getbiobrief.com/story/jpmorgan-stake-10x-genomics-txg-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.